Determination of Susceptibility to Fosfomycin and Tigecycline of Enterobacteriaceae, Particularly Escherichia coli Isolates, Producing Extended‐Spectrum β‐Lactamases from Multiple Regional Canadian Hospitals | Zendy

Carlee Beuk | Zendy; Christian Hill | Zendy; Sue Whitehead | Zendy; Edith Blondel-Hill | Zendy; Ken Wagner | Zendy; Naowarat Cheeptham | Zendy

Open Access

Determination of Susceptibility to Fosfomycin and Tigecycline of Enterobacteriaceae, Particularly Escherichia coli Isolates, Producing Extended‐Spectrum β‐Lactamases from Multiple Regional Canadian Hospitals

Author(s) -

Carlee Beuk,

Christian Hill,

Sue Whitehead,

Edith Blondel-Hill,

Ken Wagner,

Naowarat Cheeptham

Publication year - 2013

Publication title -

canadian journal of infectious diseases and medical microbiology

Language(s) - English

Resource type - Journals

eISSN - 1918-1493

pISSN - 1712-9532

DOI - 10.1155/2013/645018

Subject(s) - fosfomycin , tigecycline , enterobacteriaceae , microbiology and biotechnology , escherichia coli , biology , carbapenem resistant enterobacteriaceae , antibiotics , genetics , gene

The worldwide spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, particularly Escherichia coli, has significantly limited therapeutic options, especially for urinary tract infections. Although limited in their indications, fosfomycin and tigecycline are potential agents to treat infections due to ESBL-producing organisms. Although not routinely performed, susceptibility testing to both is necessary to ensure there is not an increase in resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research